US OptionsDetailed Quotes
IDYA240517C50000
- 0.05
- 0.000.00%
15min DelayTrading May 16 12:22 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume0 Open Interest50.00Strike Price0.00Turnover1360.09%IV30.00%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type0.0303Delta0.0155Gamma770.00Leverage Ratio-5.9974Theta0.0000Rho23.33Eff Leverage0.0002Vega
IDEAYA Biosciences Stock Discussion
Sign in to post a comment
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
6
1
Despite a high cash burn, the significant 55% annual revenue growth of IDEAYA Biosciences is encouraging. The company's limited cash burn relative to market capitalisation suggests it should be able to fuel growth with minor dilution or borrowing. Cash burn thus shouldn't be a major concern.
$IDEAYA Biosciences(IDYA.US$ IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer![]()
$IDEAYA Biosciences(IDYA.US$ @Alvinnnnnnn89 @AmyNic @Ripper1986
starting to look good from a rookie persoe tive. Thanks in advance.
starting to look good from a rookie persoe tive. Thanks in advance.
2
$IDEAYA Biosciences(IDYA.US$ @AmyNic @Ripper1986 great day. in at 18.3
Thanks to peeps pushing me to be better.
Thanks to peeps pushing me to be better.
3
3
Netflix Upgraded to Buy From Sell at CFRA
CFRA analyst Kenneth Leon double upgraded $Netflix(NFLX.US$ to Buy from Sell with a price target of $310, up from $225. The analyst believes it "will be difficult for competitors to catch" Netflix, noting it is one of the few profitable streaming providers with global scale.
Capital One Starts Ideaya Biosciences at Overweight With $29 Price Target
Capital One analyst Zegbeh Jallah initiated...
CFRA analyst Kenneth Leon double upgraded $Netflix(NFLX.US$ to Buy from Sell with a price target of $310, up from $225. The analyst believes it "will be difficult for competitors to catch" Netflix, noting it is one of the few profitable streaming providers with global scale.
Capital One Starts Ideaya Biosciences at Overweight With $29 Price Target
Capital One analyst Zegbeh Jallah initiated...
9
Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%,...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%,...
10
Gapping up
In reaction to earnings/guidance:
• $United Microelectronics(UMC.US$ +0.8% (August revs)
Other news:
• $ChannelAdvisor(ECOM.US$ +54.4% (to be acquired for $23.10 per share)
• $IVERIC bio(ISEE.US$ +42.3% (topline data from Zimura GATHER2 phase 3 clinical trialingeographic atrophy)
• $Monte Rosa Therapeutics(GLUE.US$ +10% (receives FDA clearance of Investigational New Drug Application for MRT-2359)
• $IDEAYA Biosciences(IDYA.US$ +4.9% (re...
In reaction to earnings/guidance:
• $United Microelectronics(UMC.US$ +0.8% (August revs)
Other news:
• $ChannelAdvisor(ECOM.US$ +54.4% (to be acquired for $23.10 per share)
• $IVERIC bio(ISEE.US$ +42.3% (topline data from Zimura GATHER2 phase 3 clinical trialingeographic atrophy)
• $Monte Rosa Therapeutics(GLUE.US$ +10% (receives FDA clearance of Investigational New Drug Application for MRT-2359)
• $IDEAYA Biosciences(IDYA.US$ +4.9% (re...
11
1
$IDEAYA Biosciences(IDYA.US$ pkc1 cmet combo MAY produce similar or better result than tebentafusp
No comment yet
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long